Status:
WITHDRAWN
The Use of Gastrografin to Help Alleviate Bowel Obstruction in Gastroschisis Patients.
Lead Sponsor:
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Conditions:
Gastroschisis
Bowel Obstruction
Eligibility:
All Genders
32-12 years
Phase:
PHASE4
Brief Summary
This study will investigate the use of a drug called Gastrografin to aid in bowel mobility for paediatric patients who have undergone gastroschisis surgery. Gastroschisis is an abdominal wall birth de...
Detailed Description
Gastroschisis is a congenital birth defect where the fetal abdominal organs (typically the intestines) protrude through a defect in the abdominal wall, just to the right of the umbilicus. For babies b...
Eligibility Criteria
Inclusion
- \- Diagnosis of gastroschisis
Exclusion
- Gestational age less than 32 weeks
- Birth weight less than 1500 grams
- Definitive bowel atresia based on physician diagnosis
Key Trial Info
Start Date :
August 3 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 17 2020
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT03334578
Start Date
August 3 2018
End Date
December 17 2020
Last Update
November 1 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Children's Hospital, London Health Sciences Centre
London, Ontario, Canada, N6A 5W9